Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational FcRn blocker, evaluated in a broad population of antibody positive adults with generalized myasthenia gravis. The Vivacity-MG3 study met its primary endpoint demonstrating statistically significant and clinically meaningful improvement over 24 weeks in the MG-ADLa score. Nipocalimab had a tolerable safety profile, with adverse events leading to discontinuation rates similar to placebo.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $152 from $166 at Wells Fargo
- Johnson & Johnson Reports Strong 2024 Financial Results
- Johnson & Johnson Earnings Report: Is it a Beat?
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Netflix, Seagate, J&J report quarterly beats: Morning Buzz